Published in Eur J Heart Fail on September 13, 2010
Integrating the myocardial matrix into heart failure recognition and management. Circ Res (2013) 1.00
GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective. J Diabetes Res (2015) 0.99
Growth-differentiation factor-15 and functional outcome after acute ischemic stroke. J Neurol (2012) 0.83
Cardiac biomarkers: new tools for heart failure management. Cardiovasc Diagn Ther (2012) 0.81
Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart Fail Rev (2014) 0.81
Emerging biomarkers in heart failure and cardiac cachexia. Int J Mol Sci (2014) 0.78
Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review. Heart Fail Rev (2014) 0.78
The association of growth differentiation factor-15 with left ventricular hypertrophy in hypertensive patients. PLoS One (2012) 0.78
Growth differentiation factor 15 can distinguish between hypertrophic cardiomyopathy and hypertensive hearts. Heart Vessels (2013) 0.76
Can biomarkers help to diagnose early heart failure with preserved ejection fraction? Dis Markers (2015) 0.76
Natriuretic peptides for the detection of paroxysmal atrial fibrillation. Open Heart (2015) 0.75
Plasma growth differentiation factor 15 predicts first-ever stroke in hypertensive patients. Medicine (Baltimore) (2016) 0.75
Effects of allopurinol on exercise-induced muscle damage: new therapeutic approaches? Cell Stress Chaperones (2014) 0.75
GDF 15 - A Novel Biomarker in the Offing for Heart Failure. Curr Cardiol Rev (2016) 0.75
Higher plasma levels of MR-pro-atrial natriuretic peptide are linked to less anxiety: results from the observational DIAST-CHF study. Clin Res Cardiol (2015) 0.75
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 144.02
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32
A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology (1983) 30.77
Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol (1986) 18.40
Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med (2006) 17.13
Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr (2009) 14.63
The natural history of congestive heart failure: the Framingham study. N Engl J Med (1971) 13.94
Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med (2008) 9.62
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
Biomarkers in heart failure. N Engl J Med (2008) 5.20
Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation (2007) 3.62
Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation (2009) 3.55
State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35
Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation (2010) 2.95
GDF15/MIC-1 functions as a protective and antihypertrophic factor released from the myocardium in association with SMAD protein activation. Circ Res (2006) 2.85
The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res (2006) 2.85
Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol (2007) 2.46
Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res (2006) 1.79
Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain. Eur Heart J (2008) 1.70
The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J (2005) 1.44
Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation (2007) 1.41
Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. Eur Heart J (2009) 1.40
Growth differentiation factor-15 for prognostic assessment of patients with acute pulmonary embolism. Am J Respir Crit Care Med (2008) 1.16
Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: a potential marker of erosive joint destruction. Arthritis Rheum (2007) 1.15
Cardiac myocyte gene expression profiling during H2O2-induced apoptosis. Physiol Genomics (2006) 1.12
Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. Eur J Heart Fail (2009) 1.12
Myocardial stiffness is an important determinant of the plasma brain natriuretic peptide concentration in patients with both diastolic and systolic heart failure. Eur Heart J (2006) 0.86
Six minute walk test: a simple and useful test to evaluate functional capacity in patients with heart failure. Intern Emerg Med (2008) 0.81
Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med (2004) 6.69
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00
Altered microRNA expression in human heart disease. Physiol Genomics (2007) 5.64
2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J (2014) 5.21
Pluripotency of spermatogonial stem cells from adult mouse testis. Nature (2006) 4.29
ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR-α and PGC-1. Nat Med (2011) 3.96
Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail (2010) 3.90
Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol (2003) 3.73
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet (2012) 3.66
Ca2+/calmodulin-dependent protein kinase II regulates cardiac Na+ channels. J Clin Invest (2006) 3.33
Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol (2011) 3.13
Generation of functional murine cardiac myocytes from induced pluripotent stem cells. Circulation (2008) 3.11
Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet (2004) 3.07
Low-energy control of electrical turbulence in the heart. Nature (2011) 2.75
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 2.70
Moderate hypothermia for severe cardiogenic shock (COOL Shock Study I & II). Resuscitation (2012) 2.70
The Leipzig prospective vascular ultrasound registry in radial artery catheterization: impact of sheath size on vascular complications. JACC Cardiovasc Interv (2012) 2.56
Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol (2008) 2.49
Calcium cycling in congestive heart failure. J Mol Cell Cardiol (2002) 2.46
Inhibition of elevated Ca2+/calmodulin-dependent protein kinase II improves contractility in human failing myocardium. Circ Res (2010) 2.38
Differential cardiac remodeling in preload versus afterload. Circulation (2010) 2.20
Is real time 3D transesophageal echocardiography a feasible approach to detect coronary ostium during transapical aortic valve implantation? J Cardiothorac Vasc Anesth (2013) 2.11
Incidence rates and predictors of major and minor depression in patients with heart failure. Int J Cardiol (2012) 2.05
Altered Na(+) currents in atrial fibrillation effects of ranolazine on arrhythmias and contractility in human atrial myocardium. J Am Coll Cardiol (2010) 2.04
CaMKII-dependent diastolic SR Ca2+ leak and elevated diastolic Ca2+ levels in right atrial myocardium of patients with atrial fibrillation. Circ Res (2010) 2.02
Rate dependence of [Na+]i and contractility in nonfailing and failing human myocardium. Circulation (2002) 1.95
Insulin causes [Ca2+]i-dependent and [Ca2+]i-independent positive inotropic effects in failing human myocardium. Circulation (2005) 1.93
Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci U S A (2002) 1.88
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation (2005) 1.87
N-terminal pro-brain natriuretic peptide or troponin testing followed by echocardiography for risk stratification of acute pulmonary embolism. Circulation (2005) 1.86
Randomized, double blind study of non-excitatory, cardiac contractility modulation electrical impulses for symptomatic heart failure. Eur Heart J (2008) 1.83
High precision quantitative proteomics using iTRAQ on an LTQ Orbitrap: a new mass spectrometric method combining the benefits of all. J Proteome Res (2009) 1.75
Psychosocial considerations in the European guidelines for prevention of cardiovascular diseases in clinical practice: Third Joint Task Force. Int J Behav Med (2005) 1.74
Influence of pyruvate on contractile performance and Ca(2+) cycling in isolated failing human myocardium. Circulation (2002) 1.73
Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation (2009) 1.71
First prospective, multi-centre clinical experience with a novel left ventricular quadripolar lead. Europace (2011) 1.70
Novel correlations between the genotype and the phenotype of hypertrophic and dilated cardiomyopathy: results from the German Competence Network Heart Failure. Eur J Heart Fail (2011) 1.70
Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation (2011) 1.68
Ca2+/calmodulin-dependent protein kinase II and protein kinase A differentially regulate sarcoplasmic reticulum Ca2+ leak in human cardiac pathology. Circulation (2013) 1.67
Leptin enhances the recruitment of endothelial progenitor cells into neointimal lesions after vascular injury by promoting integrin-mediated adhesion. Circ Res (2008) 1.66
Atrial overdrive pacing in patients with sleep apnea with implanted pacemaker. Am J Respir Crit Care Med (2005) 1.65
Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation (2002) 1.62
Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail (2011) 1.61
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.61
Effect of increased exercise in school children on physical fitness and endothelial progenitor cells: a prospective randomized trial. Circulation (2009) 1.61
Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcome in normotensive patients with acute pulmonary embolism. J Am Coll Cardiol (2010) 1.59
Detecting panic disorder in medical and psychosomatic outpatients: comparative validation of the Hospital Anxiety and Depression Scale, the Patient Health Questionnaire, a screening question, and physicians' diagnosis. J Psychosom Res (2003) 1.58
Laminin-alpha4 and integrin-linked kinase mutations cause human cardiomyopathy via simultaneous defects in cardiomyocytes and endothelial cells. Circulation (2007) 1.57
Differential interaction of clinical characteristics with key functional parameters in heart failure with preserved ejection fraction--results of the Aldo-DHF trial. Int J Cardiol (2013) 1.56
Heart-type fatty acid-binding protein permits early risk stratification of pulmonary embolism. Eur Heart J (2006) 1.55
Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol (2008) 1.53
Ca(2+) /calmodulin-dependent protein kinase II equally induces sarcoplasmic reticulum Ca(2+) leak in human ischaemic and dilated cardiomyopathy. Eur J Heart Fail (2014) 1.52
Peripartum cardiomyopathy--a new treatment option by inhibition of prolactin secretion. Am J Obstet Gynecol (2008) 1.51
Increased SR Ca2+ cycling contributes to improved contractile performance in SERCA2a-overexpressing transgenic rats. Cardiovasc Res (2005) 1.51
Selective upregulation of beta1-adrenergic receptors and dephosphorylation of troponin I in end-stage heart failure patients supported by ventricular assist devices. J Mol Cell Cardiol (2006) 1.50
Emerging roles of inositol 1,4,5-trisphosphate signaling in cardiac myocytes. J Mol Cell Cardiol (2008) 1.50
Plasminogen activator inhibitor-1 from bone marrow-derived cells suppresses neointimal formation after vascular injury in mice. Arterioscler Thromb Vasc Biol (2006) 1.49
Myocardial adaptation of energy metabolism to elevated preload depends on calcineurin activity : a proteomic approach. Basic Res Cardiol (2008) 1.49
Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail (2015) 1.49
2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. Rev Esp Cardiol (Engl Ed) (2015) 1.49
Invasive versus non-invasive cooling after in- and out-of-hospital cardiac arrest: a randomized trial. Clin Res Cardiol (2013) 1.48
Biventricular pacing improves the blunted force-frequency relation present during univentricular pacing in patients with heart failure and conduction delay. Circulation (2006) 1.47
Stimulated emission depletion live-cell super-resolution imaging shows proliferative remodeling of T-tubule membrane structures after myocardial infarction. Circ Res (2012) 1.47
Limitations of FKBP12.6-directed treatment strategies for maladaptive cardiac remodeling and heart failure. J Mol Cell Cardiol (2010) 1.46
Absence of leptin resistance in platelets from morbidly obese individuals may contribute to the increased thrombosis risk in obesity. Thromb Haemost (2008) 1.45
Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo. Cardiovasc Res (2011) 1.44
Self-rated health predicts adverse events during β-blocker treatment: the CIBIS-ELD randomised trial analysis. Int J Cardiol (2011) 1.44
Prognostic relevance of papillary muscle infarction in reperfused infarction as visualized by cardiovascular magnetic resonance. Circ Cardiovasc Imaging (2013) 1.43
The German CPU Registry: comparison of troponin positive to troponin negative patients. Int J Cardiol (2013) 1.43